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Introduction
Central serous chorioretinopathy (CSC) is a disease that
predominantly affects middle-aged adults. Males are
5–10 times more likely to develop CSC than females.
CSC commonly involves the sensory retina and retinal
pigment epithelium (RPE), and presents as either ink
blot or smokestack type of hyperfluorescence on fluo-
rescein angiography (FA). It may be associated with
emotional stress, a type A achievement-oriented per-
sonality, systemic steroid use and pregnancy.1 The dis-
ease is usually benign and self-limited, with good visual
recovery. However, approximately 5% of CSC cases
may have a poor visual outcome due to the disease
being chronic. Persistent subretinal fluid, central RPE
atrophy, atrophic RPE tracts inferior to the macula,
cystoid macular edema, severe RPE degeneration, and
choroidal neovascularization (CNV) are reported to
be correlated with a poor visual outcome of chronic
CSC.1,2
CNV secondary to CSC is a rare but potentially
sight-threatening complication. Photodynamic therapy
(PDT) with verteporfin has been proven to be benefi-
cial for classic subfoveal CNV secondary to age-related
macular degeneration (AMD) or pathologic myopia.
CNV secondary to CSC may be potentially ameliorated
by PDT because it usually presents as classic membrane
on FA. Until recently, there were few studies con-
cerning the outcome of PDT in patients with CSC
complicated with CNV in Asia.3 Herein, we report the
successful treatment and good visual outcome of PDT
in such a case.
Case Report
A 37-year-old man with a 6-year ocular history of
bilateral chronic CSC with multiple recurrences pre-
sented with a 3-month history of central scotoma,
reduced vision and metamorphopsia in his right eye.
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He had no history of systemic diseases. Best-corrected
visual acuity (BCVA) was 6/20 in the right eye and
6/6.7 in the left eye. There was macular hemorrhage
with exudation and pigment clumping within the pos-
terior pole in the right eye (Figure 1A), whereas an
old glial scar was evident in the posterior pole in the
left eye (Figure 1D). Intravenous FA disclosed sub-
foveal CNV in the right eye with early hyperfluores-
cence and late leakage, and multifocal areas of nodular
hyperfluorescence due to depigmentation of the RPE
(Figures 1B and 1C). FA in the left eye showed a gliotic
scar with early hyperfluorescence and late staining
without leakage (Figures 1E and 1F). Indocyanine
green angiography (ICGA) revealed subfoveal CNV
with hyperfluorescence dye leakage in the right eye
(Figure 2A), and multiple areas of choroidal vascular
hyperpermeability with associated late RPE leak in
both eyes without polypoid-like lesions (Figure 2).
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Figure 1. (A) At the initial presentation, fundus photograph showed macular hemorrhage with exudation and pigment clumping (black
arrow) and multifocal retinal pigment epithelium (RPE) depigmentation (white arrows) in the right eye. Fluorescein angiography (FA)
revealed: (B) early hyperfluorescence (arrow); and (C) late active dye leakage of classical choroidal neovascularization (CNV) with sur-
rounding block fluorescence due to subretinal hemorrhage (long arrow). Multifocal areas of nodular hyperfluorescence due to depig-
mentation of the RPE (short arrows) were also noted. (D) Fundus photograph of the left eye showed an old glial scar (black arrow) and
multifocal RPE depigmentation (white arrows). FA demonstrated: (E) early hyperfluorescence (arrow); and (F) late dye staining of the




PDT with verteporfin was applied according to
standard protocol with 2.2-mm spot size in the right
eye 2 weeks after the initial event. One month after
PDT, BCVA in the right eye had improved to 6/10
with improved symptoms. Biomicroscopic fundus ex-
amination showed resolution of the macular edema,
exudation and retinal hemorrhage with clearer foveal
light reflex (Figure 3A). FA revealed much less dye
leakage of CNV in the late phase (Figure 3B).
BCVA recovered to 6/7.5 at 3 months after PDT.
No central scotoma was found on follow-up with Amsler
Grid, and the clinical picture revealed no hemorrhage
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Figure 2. Indocyanine green angiography revealed: subfoveal choroidal neovascularization with hyperfluorescence dye leakage in the
right eye (A); and multifocal areas of choroidal vascular hyperpermeability in both eyes (A, B) without polypoid-like lesions.
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Figure 3. (A) Fundus photograph disclosed resolution of the macular edema and exudation 1 month after photodynamic therapy (PDT)
(arrow). (B) Fluorescein angiography (FA) 1 month after PDT showed obviously less dye leakage from the choroidal neovascularization
(CNV) (long arrow). The round hypofluorescent area is compatible with the spot of PDT. Multifocal areas of nodular hyperfluorescence
due to RPE depigmentation (short arrows). (C) Fundus photograph showed no more hemorrhage or exudation 3 months after PDT
(arrow), and visual acuity had improved to 6/10. (D) FA 3 months after PDT disclosed only staining with absence of CNV leakage (long
arrow). Glial scar with depigmented RPE change and window defect were noted in the juxtafoveal and parafoveal areas (short arrows).
and no exudation, with prominent fovea light reflex in
the right eye (Figure 3C). There was only staining with
absence of leakage on FA (Figure 3D). The left eye
was stationary throughout the whole course during
follow-up.
Discussion
Central serous chorioretinopathy has a heterogeneous
course. Most cases resolve spontaneously without any
treatment. However, a small but meaningful subset 
of patients with CSC may develop chronic disease.
Patients with chronic CSC may have a poor visual
prognosis, especially those with clinical features such
as persistent pigment epithelial detachment (PED)
with subretinal fluid, multiple recurrences with foveal
involvement, and subfoveal CNV.1 These CNV com-
monly arise in patients with a history of longstanding
CSC, persistent or recurrent attacks, chronic diffuse
epitheliopathy, or an older age at presentation. Our
patient belongs to this group of patients. The exact
pathogenesis for the development of CNV in patients
with CSC is unclear. We hypothesize that chronic de-
compensation or disruption at the RPE-Bruch mem-
brane complex together with ischemic changes at the
choriocapillaries may be important factors in CNV.
CSC develops primarily as a result of choroidal
vascular hyperpermeability evidenced by ICGA study.
PDT is a selective therapeutic modality that has been
shown to occlude the hyperproliferative vessels and
normalize the calibers of dilated and congested cho-
roidal vasculature while leaving normal choroidal tissue
unharmed, as compared to conventional laser ther-
apy.3 Recently, PDT with verteporfin has been used in
the treatment of chronic CSC, with beneficial visual
outcomes in the majority of patients in Western re-
ports.3–7 In the literature, there are few reports con-
cerning PDT treatment of CSC in Asia.3,5 We found 
a favorable anatomic and functional outcome at the
1- and 3-month follow-ups in a Chinese patient who
remained stable without recurrence of CNV 12 months
after PDT treatment.
ICGA is a very useful diagnostic tool with the
advantage of being able to establish the correct diag-
nosis of CSC compared with FA. Characteristic ICGA
findings include hyperpermeability of choroidal ves-
sels with associated active RPE leaks, and multiple
presumed occult serous RPE detachments in both
eyes.8,9 Differentiating CSC from other retinal dis-
eases is the absence of polypoidal lesions and hot
spots that are seen in polypoid choroidal vasculopathy
and AMD.5,10,11
PDT treatment in patients with CSC associated
with CNV might be successful because PDT also affects
the longstanding non-neovascular component of CSC.6
ICGA-guided PDT with verteporfin seems to aid in
the resolution of exudative detachment in patients
with chronic CSC.9 PDT treatment is associated with
a rapid reduction in subretinal fluid and improvement
in visual acuity. In our patient, PDT was able to treat
both the disease itself and CNV. Furthermore, PDT
has the advantage of being less invasive than submac-
ular surgery.2 Due to long-term safety concerns and
the possible risk of choroidal damage after PDT, recent
reports have focused on reduced-dose verteporfin PDT
for chronic CSC instead of the traditional standard
protocol.12,13 RPE tear following PDT in the treat-
ment of CNV associated with AMD has also been
reported to be a potential risk of PDT.14
In conclusion, PDT with verteporfin is an effective
and promising treatment with good visual outcome
in patients with CSC associated with CNV. Patient
selection and early intervention remain vital in the
treatment of this group of patients. Further prospec-
tive study would be beneficial to demonstrate the long-
term safety and efficacy of PDT in treating CNV
secondary to CSC in the Chinese population.
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